Latest Conference

Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.

Although HIV PrEP uptake is gradually increasing, usage remains low among key at-risk populations.

What are the characteristics and demographics of the chronic hepatitis B patients who develop severe outcomes?

Experts discuss a range of the most topical infectious disease research, presented at the recent IDWeek 2022 conference.

In communities of color, hesitancy, mistrust, and access issues all drove low COVID-19 vaccination rates during the pandemic.

Previously thought to be difficult or impossible, one study found HCV and drug use can be treated concurrently in young adults.

How do we increase HIV PrEP uptake? “I think the biggest takeaway here is that people need options,” said Travis Sanchez, DVM, MPH.

Is it safe and beneficial to administer a second immunomodulator in patients with moderate COVID-19? How do we identify which patients are likely to progress to severe disease?

Lodise breaks down significant findings from his 8 IDWeek 2022 posters.

Remdesivir was the first FDA-approved drug to fight COVID-19, but how has it held up against the latest variants?

Northwestern Medicine developed a testing strategy using a two-step algorithm to improve diagnostic accuracy and treatment outcomes.

One HIV clinical care program in Delaware looked into strategies to increase immunization rates to decrease severe disease as well as minimize hospital capacity.

It’s not enough to have accurate infectious disease diagnostics, they must be accessible to the patients most affected.

Encouraging ICU physicians to utilize rapid diagnostics, like the FilmArray Pneumonia Panel, may improve patient outcomes.

Venatorx Pharmaceuticals is advancing the fight against difficult-to-treat, drug-resistant, gram-negative bacteria with a successful phase 3 clinical trial of its investigational antibiotic cefepime-taniborbactam.

Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in an hour.

A multicenter, retrospective observational study looked at appropriate antibiotics for the treatment in this patient population.

Investigators examined the profiles of the HepB-CPG vaccine and HepB-alum vaccines to study the onset of select immune-mediated diseases, herpes zoster, or anaphylaxis.

Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.

A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.

Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.

Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.

At IDWeek 2022, Erica Stohs, MD, MPH, presented surprising findings about unnecessary antibiotics in a cohort coinfected with COVID-19 and pneumonia.

The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

There is a significant need for C difficile treatments that don’t destroy the microbiome.